BioLineRx and Hemispherian Present Phase 1/2a Clinical Study and Pre-Clinical Updates, Including Brain PK/PD Data, at SNO 2026
BioLineRx and Hemispherian presented two posters on GLIX1, a first-in-class oral TET2 activator, at the 31st Society for Neuro-Oncology Annual Meeting. The Phase 1/2a study in high-grade glioma has initiated its fourth cohort with no significant treatment-emergent adverse events, and remaining cohorts will add a window-of-opportunity setting to directly assess brain penetration in human tumor tissue. Preclinical data showed robust, dose-dependent antitumor activity across multiple GBM models, including tumor eradication in the SNB19 model and growth inhibition in a TMZ-resistant PDX where TMZ failed, with confirmed brain penetration and dose-dependent 5hmC increases.
Key figures
- Drug Name
- GLIX1
- Phase Of Trial
- Phase 1/2a
- Data timing
- study results expected first half of 2027
- Cohort status
- fourth cohort dosing initiated
- Trial identifier
- NCT07464925
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.